These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 16515984

  • 21. Delay of surgery in men with low risk prostate cancer.
    O'Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, Catalona WJ.
    J Urol; 2011 Jun; 185(6):2143-7. PubMed ID: 21496847
    [Abstract] [Full Text] [Related]

  • 22. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [Abstract] [Full Text] [Related]

  • 23. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA.
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [Abstract] [Full Text] [Related]

  • 24. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV.
    Cancer; 2006 Dec 01; 107(11):2597-603. PubMed ID: 17039498
    [Abstract] [Full Text] [Related]

  • 25. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.
    Cancer; 2007 Apr 01; 109(7):1273-8. PubMed ID: 17315165
    [Abstract] [Full Text] [Related]

  • 26. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
    van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, van Leeuwen PJ, Roobol MJ, Schröder FH, Hugosson J, Swedish and Dutch sections of the European Randomized Study of Screening for Prostate Cancer.
    Cancer; 2010 Mar 01; 116(5):1281-90. PubMed ID: 20066716
    [Abstract] [Full Text] [Related]

  • 27. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS, Bianco FJ, Scardino PT, Eastham JA.
    J Urol; 2006 Aug 01; 176(2):564-8. PubMed ID: 16813890
    [Abstract] [Full Text] [Related]

  • 28. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
    Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ.
    J Urol; 2007 Feb 01; 177(2):505-9. PubMed ID: 17222621
    [Abstract] [Full Text] [Related]

  • 29. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.
    J Urol; 2009 Nov 01; 182(5):2250-5. PubMed ID: 19758614
    [Abstract] [Full Text] [Related]

  • 30. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.
    J Urol; 2007 Nov 01; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [Abstract] [Full Text] [Related]

  • 31. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
    Sengupta S, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP, Blute ML.
    J Urol; 2006 Aug 01; 176(2):559-63. PubMed ID: 16813889
    [Abstract] [Full Text] [Related]

  • 32. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J, Flanigan RC, Meydani M, Choi YK, Freeman VL.
    J Urol; 2007 Dec 01; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [Abstract] [Full Text] [Related]

  • 33. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr 01; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 34. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis.
    Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM.
    BJU Int; 2012 Jul 01; 110(2):211-6. PubMed ID: 22093486
    [Abstract] [Full Text] [Related]

  • 35. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS.
    BJU Int; 2009 Jul 01; 104(2):195-9. PubMed ID: 19191784
    [Abstract] [Full Text] [Related]

  • 36. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.
    J Urol; 2006 Dec 01; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [Abstract] [Full Text] [Related]

  • 37. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ.
    J Urol; 2009 Aug 01; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [Abstract] [Full Text] [Related]

  • 38. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
    D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW.
    Cancer; 2007 Jul 01; 110(1):56-61. PubMed ID: 17530618
    [Abstract] [Full Text] [Related]

  • 39. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R.
    BJU Int; 2006 Jun 01; 97(6):1173-8. PubMed ID: 16686707
    [Abstract] [Full Text] [Related]

  • 40. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.
    Urology; 2009 May 01; 73(5):1087-91. PubMed ID: 19195695
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.